Table 4 Cost-Effectiveness results for sensitivity analyses
Based on ITT data of ROCKET AF trial (switch to aspirin for rivaroxaban and VKA-treated patients) | ||
|---|---|---|
| Â | Rivaroxaban | VKA |
Total costs (€) | 7,927 | 8,020 |
QALYs | 6.49 | 6.29 |
ICER/QALY Gained (€) | NA | Riv. Dom |
Based on SOT data of ROCKET AF trial (switch to no treatment for all patients) | ||
Total costs (€) | 9,952 | 10,029 |
QALYs | 6.24 | 6.04 |
ICER/QALY Gained (€) | NA | Riv. Dom. |
Based on ITT data of ROCKET AF trial (switch to no treatment for all patients) | ||
Total costs (€) | 9,597 | 9,554 |
QALYs | 6.29 | 6.10 |
ICER/QALY Gained (€) | NA | 233 |